Table II.
Univariate analyses showing the overall survival rate of CCC patients.
| Parameters/categories | No. of cases (n) | Mean survival time in months (95% CI) | P-value |
|---|---|---|---|
| Age | |||
| <70 | 66 | 18.1 (13.0–23.2) | 0.352 |
| ≥70 | 21 | 23.7 (13.7–33.7) | |
| Gender | |||
| Male | 46 | 19.0 (13.8–24.1) | 0.393 |
| Female | 41 | 17.2 (8.3–26.1) | |
| Histological grade | |||
| G1 | 28 | 35.0 (27.9–42.1) | <0.001a |
| G2 | 38 | 13.8 (11.6–16.0) | |
| G3 | 21 | 10.6 (0.1–21.1) | |
| TNM stage | |||
| I-II | 77 | 20.6 (15.5–25.7) | 0.007a |
| III-IV | 10 | 12.1 (9.1–15.1) | |
| Lymph node metastasis | |||
| Negative | 60 | 23.8 (17.7–29.9) | 0.005a |
| Positive | 27 | 14.6 (7.5–21.7) | |
| CA-199 | |||
| <35 | 39 | 22.8 (16.5–29.1) | 0.100 |
| ≥35 | 48 | 16.3 (11.9–20.7) | |
| Venous/lymphatic invasion | |||
| Negative | 44 | 19.0 (12.5–25.5) | 0.822 |
| Positive | 43 | 18.8 (12.2–25.4) | |
| Perineural invasion | |||
| Negative | 45 | 18.1 (10.8–25.4) | 0.586 |
| Positive | 42 | 18.8 (13.5–24.1) | |
| HOXD10 | |||
| Negative | 36 | 12.5 (8.3–16.7) | <0.001a |
| Positive | 51 | 24.2 (19.8–28.6) | |
| RHOC | |||
| Negative | 49 | 23.8 (17.8–29.8) | <0.001a |
| Positive | 38 | 13.8 (5.2–22.4) |
a
Statistically significant. G1, well-differentiated; G2, moderately-differentiated; G3, poorly-differentiated; CCC, cholangiocellular carcinoma.